surpass trial tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 Efficacy and safety of tirzepatide

This drives preferential fat loss instead of lean muscle

Learn what causes "Ozempic teeth," how GLP-1 side effects affect your oral health, and what you can do.

ANI will not be responsible in any way for the content of the same.)

"Even on the darkest of days, Freya continues to smile and fight like the warrior she is," her family says

Learn the common reasons behind this side effect, how long it lasts, and fast tips to find relief safely.

During the study period, 113 patients (8-year cumulative incidence 9.3%) compared to 130 non-surgical patients (8-year cumulative incidence 11.3%) suffered from MACE or all-cause mortality (HR 0.76, 95%CI 0.590.98), and 69 patients (8-year cumulative incidence 5.1%) compared to 92 non-surgical patients (8-year cumulative incidence 7.6%) suffered from a non-fatal MACE (HR 0.68, 95%CI 0.490.93)